Celiac disease: from etiological factors to evolving diagnostic approaches Anantdeep KaurOlga ShimoniMichael Wallach Review 19 June 2017 Pages: 1001 - 1012
Clinical practice guideline for post-ERCP pancreatitis Tetsuya MineToshio MorizaneTooru Shimosegawa Review 26 June 2017 Pages: 1013 - 1022
Diagnostic accuracy of demarcation of undifferentiated-type early gastric cancer after Helicobacter pylori eradication Yusuke HoriuchiJunko FujisakiHiroshi Takahashi Original Article—Alimentary Tract 12 January 2017 Pages: 1023 - 1030
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis Yasuo SuzukiSatoshi MotoyaMamoru Watanabe Original Article—Alimentary Tract Open access 20 March 2017 Pages: 1031 - 1040
Natural history of chronic hepatitis B virus infection in children in Japan: a comparison of mother-to-child transmission with horizontal transmission Tomoko TakanoHitoshi TajiriStephen Brooks Original Article—Liver, Pancreas, and Biliary Tract 09 February 2017 Pages: 1041 - 1050
Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes Masaki KatoSusumu Hamada-TsutsumiManae Suzuki Kurokawa Original Article—Liver, Pancreas, and Biliary Tract 14 February 2017 Pages: 1051 - 1063
Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma An-Ye ZhangChing-Lung LaiMan-Fung Yuen Original Article—Liver, Pancreas, and Biliary Tract 28 March 2017 Pages: 1064 - 1074
Comment to: “Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs” Marko LucijanicSead ZigaIvica Grgurevic Letter to the Editor 16 June 2017 Pages: 1075 - 1076
Response to the Letter by Lucijanic et al., regarding our manuscript “Management and outcome of gastro-intestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs” Jan Beyer-Westendorf Letter to the Editor 28 June 2017 Pages: 1077 - 1078
Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis Yasuo SuzukiSatoshi MotoyaMamoru Watanabe Erratum 12 April 2017 Pages: 1079 - 1079